Compare Gogoro Inc (GGR) vs Merck & Co., Inc. (MRK) Price & Performance

Gogoro IncTrade

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Gogoro Inc vs Merck & Co., Inc. — how do they compare? Gogoro Inc trades at $2.51 (market cap $52.19M), while Merck & Co., Inc. trades at $133.42 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 6165.4× Gogoro Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals.

	GGR	MRK
Market Cap	$52.19M	$321.77B
Sector	Technology	Health
52-Week High	$7.50	$131.84
52-Week Low	$2.55	$77.60
Enterprise Value	$354.63M	$368.53B
Dividend Yield	—	2.61%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gogoro Inc

GGR trades at $2.46, down 4.65% today, with a bearish technical signal despite oversold RSI readings. The company reported Q1 2026 revenue of $281.48M with negative net income of -$79.97M, though operating cash flow improved to $35.90M. Valuation metrics show low P/S (0.14) and P/B (0.45) ratios, but profitability remains weak with negative ROE (-50.38%) and net margins (-24.68%).

The outlook remains challenging with persistent losses and negative cash flow, though management highlights margin improvements and subscriber growth. Key risks include execution on profitability and competitive pressures. Analyst consensus is neutral (100% Hold), reflecting cautious sentiment amid ongoing turnaround efforts.

Merck & Co., Inc.

MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.

MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GGR

View details →

MRK

Merck reports 5% revenue growth in Q2 2026, boosted by KEYTRUDA and pipeline drugs, with positive analyst outlook.Danny Green · 12 hours agoBullish Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest.24/7 Wall Street · 14 hours agoBullish Bio-Techne reports flat FY2026 revenue, EPS rise, and confirms $11.3B acquisition by Merck KGaA.PRNewsWire · 16 hours agoBullish View details →

About Gogoro Inc

Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.